Moderators: Stuart C Sweet, MD, PhD and Stephan Ensminger, MD, DPhil

Translating Tissue Engineered Heart Repair
Wolfram Zimmermann, MD, University Medical Center Goettingen, Goettingen, Germany
Myocardium damaged during a heart attack does not regenerate and the weakened muscle results in heart failure. In this context an attractive therapeutic strategy for myocardial remuscularization is transplantation of engineered heart muscle from pluripotent stem cells, such as embryonic, induced or parthenogenetic stem cells. This presentation will describe various strategies using induced pluripotent stem cell (iPSC)-derived cardiomyocytes and illustrate how effective the different strategies work and contribute to the recipient’s heart function. In addition safety concerns and limitations are critically reviewed.

Featured Presentation: (1) Worldwide First Successful and Reproducable Long-Term Survival up to Half a Year: Completed Preclinical Study with Life-Supporting Orthotopic Pig-to-Baboon Cardiac Xenotransplantation (oXHTx) Fullfilling the ISHLT Prerequisite for Clinical Cardiac Xenotransplantation
Paolo Brenner, MD, Ludwig Maximilian University of Munich, Munich, Germany

Featured Discussant Q & A
Richard N. Pierson III, MD, Harvard University / Massachusetts General Hospital, Boston, MA, USA

Management of Lung Failure in 2040: Artificial Lung or Regeneration?
Shaf Keshavjee, MD, MSc, FRCSC, FACS, University of Toronto, Toronto, Canada
The field of lung transplant has made significant advances over the last several decades. Major obstacles are still donor shortage, proper selection of candidates, primary graft dysfunction, and chronic lung allograft dysfunction. This presentation starts with the current ‘gold standard’ as baseline and will then speculate how treatment modalities will have changed by 2040. New technology such as EVLP and bioengineered lungs are discussed and new innovations such as novel biomarkers and new ways to treat infected donors are described. Finally, the speaker will finish up with his vision of lung failure management in 2040.

Featured Presentation: (2) A European Multi‐Center, Randomized, Double‐Blind Trial of Pirfenidone in Bronchiolitis‐Obliterans‐Syndrome Grade 1‐3 in Lung Transplant Recipients (European Trial of Pirfenidone in BOS (EPOS))
Michael Perch, MD, Rigshospitalet / University Hospital of Copenhagen, Copenhagen, Denmark

Featured Discussant Q & A
Marie Budev, DO, MPH FCCP, The Cleveland Clinic, Cleveland, OH, USA
 

Continuing Education Information

Learning Objectives – at the conclusion of this session, attendees will be able to:

• Describe various strategies using induced pluripotent stem cell (PSC) derived cardiomycocytes
• Illustrate how effective the different strategies work and contribute to the recipient’s heart function
• Learn how treatment modalities will have changed by 2040
• Learn about new technology such as EVLP and bioengineered lungs and new innovations such as novel biomarkers and new ways to treat infected donors
   

Target Audience – The target audience for the May Plenary Session includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.

Activity Designed to Change – This activity is designed to change knowledge, competence and performance.

Learning Attributes   Patient Care and Medical Knowledge

Disclosures – Current guidelines state that participants in continuing medical and allied health professional education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation or service as Chair/Planner. Disclosures will be distributed in the Learner Notification that you receive as a participant prior to the live virtual session. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Disclaimer – The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the ISHLT.

Documenting CME Credits – The ISHLT provides CME certificates to those who have participated in an ISHLT educational activity. The ISHLT does not submit credits to regulating bodies or certifying organizations on behalf of the participants. It is the participants responsibility to submit proof of credits on his or her own behalf.